Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/springer-journals/18f-fdg-pet-in-patients-with-primary-systemic-anaplastic-large-cell-bMzyrNjmvr
References (28)
-
X. Cahu, C. Bodet-Milin, E. Brissot, H. Maisonneuve, R. Houot, N. Morineau, P. Solal-Celigny, P. Godmer, T. Gastinne, P. Moreau, A. Moreau, T. Lamy, F. Kraber-Bodere, S. Gouill (2011)
18 F-fluorodeoxyglucose–positron emission tomography before, during and after treatment in mature T/NK lymphomas: a study from the GOELAMS group -
P. Zinzani (2011)
PET in T-Cell LymphomaCurrent Hematologic Malignancy Reports, 6
-
F. Vega, L. Medeiros, Vasiliki Leventaki, Coralyn Atwell, J. Cho-Vega, L. Tian, F. Claret, G. Rassidakis (2006)
Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma.Cancer research, 66 13
-
G. Rassidakis, A. Sarris, M. Herling, R. Ford, F. Cabanillas, T. McDonnell, L. Medeiros (2001)
Differential expression of BCL-2 family proteins in ALK-positive and ALK-negative anaplastic large cell lymphoma of T/null-cell lineage.The American journal of pathology, 159 2
-
S. Park, S. Kim, Dae-Ho Lee, Y. Jeong, Yunjeong Bae, E. Han, J. Huh, C. Suh (2008)
Primary Systemic Anaplastic Large Cell Lymphoma in Korean Adults: 11 Years' Experience at Asan Medical CenterYonsei Medical Journal, 49
-
R. Gatenby, R. Gillies (2004)
Why do cancers have high aerobic glycolysis?Nature Reviews Cancer, 4
-
R. Wahl, H. Jacene, Y. Kasamon, M. Lodge (2009)
From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid TumorsJournal of Nuclear Medicine, 50
-
Zhoulei Li, N. Graf, K. Herrmann, A. Jünger, M. Aichler, A. Feuchtinger, A. Baumgart, A. Walch, C. Peschel, M. Schwaiger, A. Buck, U. Keller, T. Dechow (2012)
FLT-PET is superior to FDG-PET for very early response prediction in NPM-ALK-positive lymphoma treated with targeted therapy.Cancer research, 72 19
-
G. Semenza (1998)
Hypoxia-inducible factor 1: master regulator of O2 homeostasis.Current opinion in genetics & development, 8 5
-
J. Sun, K. Park, S. Sheen, Joon-Kee Yoon, Seok‐Nam Yoon, K. Lee, S. Hwang (2009)
Clinical usefulness of the fluorodeoxyglucose (FDG)-PET maximal standardized uptake value (SUV) in combination with CT features for the differentiation of adenocarcinoma with a bronchioloalveolar carcinoma from other subtypes of non-small cell lung cancers.Lung cancer, 66 2
-
Ji Kim, H. Kim, Jae Kim, D. Moon, Y. Kim, D. Kim, Seung-Ii Park, Young Park, J. Ryu (2010)
18F-FDG PET/CT is Useful for Pretreatment Assessment of the Histopathologic Type of Thymic Epithelial TumorsNuclear Medicine and Molecular Imaging, 44
-
H. Schöder, A. Noy, M. Gönen, L. Weng, David Green, Y. Erdi, S. Larson, H. Yeung (2005)
Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 21
-
M. Marzec, M. Kasprzycka, Xing-ge Liu, M. El-Salem, Krzysztof Hałasa, P. Raghunath, R. Bucki, P. Włodarski, M. Wasik (2007)
Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathwayOncogene, 26
-
M. Juweid (2011)
FDG-PET/CT in lymphoma.Methods in molecular biology, 727
-
J. Feeney, S. Horwitz, M. Gönen, H. Schöder (2010)
Characterization of T-cell lymphomas by FDG PET/CT.AJR. American journal of roentgenology, 195 2
-
A. Barreca, E. Lasorsa, L. Riera, R. Machiorlatti, R. Piva, M. Ponzoni, I. Kwee, F. Bertoni, P. Piccaluga, S. Pileri, G. Inghirami (2011)
Anaplastic lymphoma kinase in human cancer.Journal of molecular endocrinology, 47 1
-
P. Khong, Clara Pang, Raymond Liang, Yok-Lam Kwong, Wing Au (2008)
Fluorine-18 fluorodeoxyglucose positron emission tomography in mature T-cell and natural killer cell malignanciesAnnals of Hematology, 87
-
E. Pakos, A. Fotopoulos, J. Ioannidis (2005)
18F-FDG PET for evaluation of bone marrow infiltration in staging of lymphoma: a meta-analysis.Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 46 6
-
M. Juweid, S. Stroobants, O. Hoekstra, F. Mottaghy, M. Dietlein, A. Guermazi, G. Wiseman, L. Kostakoglu, K. Scheidhauer, A. Buck, R. Naumann, K. Spaepen, R. Hicks, W. Weber, S. Reske, M. Schwaiger, L. Schwartz, J. Zijlstra, B. Siegel, B. Cheson (2007)
Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 25 5
-
O. Merkel, F. Hamacher, D. Laimer, E. Sifft, Z. Trajanoski, M. Scheideler, G. Egger, M. Hassler, C. Thallinger, Ana-Iris Schmatz, S. Turner, R. Greil, L. Kenner (2010)
Identification of differential and functionally active miRNAs in both anaplastic lymphoma kinase (ALK)+ and ALK− anaplastic large-cell lymphomaProceedings of the National Academy of Sciences, 107
-
J. Vose, J. Armitage, D. Weisenburger (2008)
International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 25
-
B. Cheson, B. Pfistner, M. Juweid, R. Gascoyne, L. Specht, S. Horning, B. Coiffier, R. Fisher, A. Hagenbeek, E. Zucca, S. Rosen, S. Stroobants, T. Lister, R. Hoppe, M. Dreyling, K. Tobinai, J. Vose, J. Connors, M. Federico, V. Diehl (2007)
Revised response criteria for malignant lymphoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 25 5
-
Yon Sung, K. Lee, Byung‐Tae Kim, J. Choi, Y. Shim, C. Yi (2006)
18F-FDG PET/CT of thymic epithelial tumors: usefulness for distinguishing and staging tumor subgroups.Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 47 10
-
B. Cheson, S. Horning, B. Coiffier, M. Shipp, R. Fisher, J. Connors, T. Lister, J. Vose, A. Grillo‐López, A. Hagenbeek, F. Cabanillas, Donald Klippensten, W. Hiddemann, R. Castellino, N. Harris, J. Armitage, W. Carter, R. Hoppe, G. Canellos (1999)
Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 17 4
-
P. Piccaluga, A. Gazzola, C. Mannu, C. Agostinelli, F. Bacci, E. Sabattini, C. Sagramoso, R. Piva, F. Roncolato, G. Inghirami, S. Pileri (2011)
Pathobiology of Anaplastic Large Cell LymphomaAdvances in Hematology, 2010
-
S. Advani (2010)
Targeting mTOR pathway: A new concept in cancer therapyIndian Journal of Medical and Paediatric Oncology : Official Journal of Indian Society of Medical & Paediatric Oncology, 31
-
C. Suh, Yoon-Koo Kang, J. Roh, M. Kim, Jae Kim, J. Huh, Jeong Lee, Y. Jang, B. Lee (2008)
Prognostic Value of Tumor 18F-FDG Uptake in Patients with Untreated Extranodal Natural Killer/T-Cell Lymphomas of the Head and NeckJournal of Nuclear Medicine, 49
-
R. Chiarle, C. Voena, C. Ambrogio, R. Piva, G. Inghirami (2008)
The anaplastic lymphoma kinase in the pathogenesis of cancerNature Reviews Cancer, 8
- Publisher
- Springer Journals
- Copyright
- Copyright © 2013 by Korean Society of Nuclear Medicine
- Subject
- Medicine & Public Health; Nuclear Medicine; Imaging / Radiology; Orthopedics; Cardiology; Oncology
- ISSN
- 1869-3474
- eISSN
- 1869-3482
- DOI
- 10.1007/s13139-013-0224-6
- pmid
- 24900120
- Publisher site
- See Article on Publisher Site
Abstract
Nucl Med Mol Imaging (2013) 47:249–256 DOI 10.1007/s13139-013-0224-6 ORIGINAL ARTICLE F-FDG PET in Patients with Primary Systemic Anaplastic Large Cell Lymphoma: Differential Features According to Expression of Anaplastic Lymphoma Kinase Dong Yun Lee & Jong Jin Lee & Jin Yong Kim & Seol Hoon Park & Sun-Young Chae & Shin Kim & Dok Hyun Yoon & Cheolwon Suh & Jooryung Huh & Jin-Sook Ryu Received: 13 June 2013 /Revised: 24 July 2013 /Accepted: 5 August 2013 /Published online: 23 August 2013 Korean Society of Nuclear Medicine 2013 Abstract rate in negative-interim PET was higher than positive-interim Purpose Primary systemic anaplastic large cell lymphoma PET (100 % vs 37.5 %, P =0.02); however, there was no such (ALCL) is divided into two entities according to the expres- difference in ALK-positive ALCL (100 % vs 75 %, P =0.19). sion of anaplastic lymphoma kinase (ALK). We investigated The 3-year progression-free survival (PFS) was not signifi- F-fluorodeoxyglucose positron emission tomography cantly different between ALK-positive and ALK-negative ( F-FDG PET) findings in primary systemic ALCL according ALCL (72.7 % vs 47.6 %, P =0.34). In ALK-negative ALCL, to ALK expression. negative interim and post-therapy PET patients had better 3- Methods Thirty-seven patients who
Journal
Nuclear Medicine and Molecular Imaging – Springer Journals
Published: Aug 23, 2013